Anthem Biosciences Ltd Q1 FY27 Earnings Call: Secures 60% Order Book Visibility, Adds New Large Pharma Client

Anthem Biosciences Ltd held its Q1 FY27 earnings call on July 21, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Soft Topline, Resilient Margins in Seasonally Weak Quarter

• Consolidated revenue of Rs.418 crore — CRDMO segment contributed 81.5% (Rs.341 crore) and specialty ingredients contributed 18.5% (Rs.78 crore).
• EBITDA of Rs.176 crore, margin 39.6% — includes other income of Rs.25 crore; margin improved year-on-year supported by cost focus and yield optimization.
• PAT of Rs.120 crore, margin 27.1% — Profit Before Tax stood at Rs.145 crore; net cash position as of 30 Jun 2026 was Rs.1,720 crore.
• Revenue declined ~25% YoY — driven by timing shifts in customer deliveries, with a higher concentration scheduled in the second half of FY 2026-2027.
• Q1 guided as softest quarter of FY 2026-2027 — management expects sequential growth from Q2 FY 2026-2027 onward; volatility deemed inherent to the business.
• Specialty ingredients segment faced supply chain pressures due to geopolitical factors — management expressed confidence in decent growth by end of FY 2026-2027.

60% Visibility Anchors Double-Digit Full-Year Outlook

• 60% order book visibility after Q1 for FY 2026-2027 — covers the whole business, though primarily applies to the CDMO segment; specialty ingredients is a month-on-month B2B business.
• At start of FY 2026-2027, management had 50% of the current year's order book in hand — confidence to achieve the remaining 50% through new client onboarding and existing client volume increases.
• Remaining 40% of revenue expected from three sources — new client wins (including recently onboarded large pharma customers), existing customers increasing volumes, and positive clinical outcomes from biotech clients leading to new orders.
• One new large pharma customer added in Q1 — significant revenue contribution expected in later quarters of FY 2026-2027; agreement not yet signed.
• Existing large biotech customer acquired by a big pharma ~one month ago — impact not material for remainder of FY 2026-2027; "provides a foot in the door" with the acquirer.
• Active pipeline of 100+ early-stage programs and 10 late-phase molecules — includes a couple of ADC molecules; 4 molecules commercialized in FY 2025-2026; late-phase assets are 18-24 months from commercialization.
• Order book for FY 2026-2027 indicates growth vs prior sales from recently commercialized molecules — sizable supplies depend on market penetration of innovator launches and are expected to take a couple of years.

Unit 4 Buildout Positions for Next Growth Phase

• Unit 1 utilization at 75-78% in Q1 FY 2026-2027 — custom synthesis, similar to FY 2025-2026 exit of 74%.
• Unit 2 utilization at 50% — covers both custom synthesis (post 130 kiloliter expansion) and fermentation (across 140 kiloliters).
• Unit 3 (Neo Anthem) utilization at 30-35% — up from ~15% in FY 2025-2026, driven by new projects in peptide synthesis and oncology manufacturing rather than production shifts.
• Management expects all three units to reach optimum utilization within two years — deferred deliveries from Q1 provide confidence of improving utilization.
• Unit 4 capex outlay of Rs.1,200 crore (Phase 1) — adds 365 kL custom synthesis, 100 kL fermentation, and a food/nutra plant; commissioning targeted by end of FY 2027-2028.
• CAPEX of ~Rs.700 crore guided for FY 2026-2027 — split ~50-50 across FY 2026-2027 and FY 2027-2028; capex to remain elevated in FY 2027-2028 then decline.
• Unit 4 capacity primarily targets 14 existing commercial molecules and 10 late-stage molecules — commercialization growth needs to materialize for absorption.

Cost Discipline Preserves Industry-High Margins

• EBITDA margin expanded year-on-year in Q1 FY 2026-2027 — supported by disciplined cost focus, yield optimization, and employee productivity; management committed to sustaining revenue growth in line with long-term historical performance.
• Material margin improved in Q1 FY 2026-2027 despite slower top-line growth — cost advantages from new technologies including flow chemistry and biocatalysis.
• Employee cost rate of 18.8% in Q1 FY 2026-2027 — elevated due to lower revenue base; management guides full-year FY 2026-2027 employee cost rate of ~13%.
• Other expenses guided at 9-10% of revenue for FY 2026-2027 — Q1 level consistent with this range; no one-time items in the quarter.
• ESOP cost of Rs.9 crore for full-year FY 2026-2027 — down from Rs.16 crore in FY 2025-2026; expected to decline further to ~Rs.5 crore in FY 2027-2028.
• Working capital normal in Q1 — receivables declined due to weaker revenue; inventory increased slightly in preparation for Q2 and Q3 deliveries.
• Effective tax rate expected to normalize to ~25-25.5% for FY 2026-2027 — as subsidiary Neo Anthem is expected to reach breakeven and potentially become profitable this year.

Semaglutide Approval and Demand Reacceleration in H2

• Semaglutide API awaiting CDSCO approval expected within a quarter or two — management expects approval "sometime this year" (FY 2026-2027), which is the first gate to enable domestic sales.
• Sampling with major domestic players complete — customers are ready to proceed once regulatory approval is received; overseas customers sampled but company is "not currently targeting other markets".
• Management reiterated "industry high" margins sustainable in FY 2026-2027 — citing 60% order book already secured and cost advantages from new technologies.
• Customer deferments impacted Q1 but do not affect long-term demand — occur when customers destock after over-anticipating sales in specific geographies (China, Germany, France) or face delayed regulatory approvals in new markets.
• Management advised evaluating results on a full-year, holistic basis — Ajay Bhardwaj assured the company will grow in FY 2026-2027 consistent with past performance, and cautioned that lumpiness in quarterly CDMO revenue is normal.
• GLP-1 described as a "long-term robust opportunity" — but commercial supply of semaglutide API has not yet started; near-term revenue contribution is contingent on CDSCO approval timing.

Early AI Adoption with Focus on Differentiation

• Management sees AI as an evolving landscape with "limited concrete use cases so far" — separating hype from reality; feedback from large pharma clients on their AI usage has been vague with no definitive patterns yet.
• Near-term AI applications identified in quality assurance and manufacturing — automating document review in QA and optimizing manufacturing resource allocation.
• AI-driven drug target discovery could create more work for Anthem — drug candidates still require lab production and development, potentially increasing demand for CDMO services.
• Over the next three to four years, Anthem is actively seeking AI use cases — management aims "not to miss the opportunity as applications develop".
• Customers value three factors when choosing Anthem over other CDMOs — keeping promises, innovation (helping create new IP), and regulatory compliance track record.
• Hardest capability to preserve as Anthem scales is staying ahead of rapid industry evolution — lifecycle from specialty to commoditization is shrinking; management highlighted that "failure to sharpen tools and differentiate risks being left behind".